Impact of specialty pharmacy collaboration with rheumatology clinics to improve the achievement of treat-to-target goals in patients with rheumatoid arthritis: a pilot study
- 9 November 2022
- journal article
- research article
- Published by Taylor & Francis in Baylor University Medical Center Proceedings
- Vol. 36 (2) , 190-194
Abstract
In rheumatoid arthritis, the use of Routine Assessment of Patient Index Data 3 (RAPID3) assessments to meet treat-to-target goals is endorsed by the 2021 American College of Rheumatology guidelines. In November 2020, the Baylor Scott & White specialty pharmacy implemented a new service that included more frequent collection of RAPID3 scores and standardized provider communication for patients co-managed by a Baylor Scott & White rheumatology clinic. The objective was to evaluate the impact of this new service on rheumatoid arthritis disease activity. Before the new service started, patients followed a protocol of RAPID3 assessments that occurred every 6 months; once the service began, patients were followed using an algorithm in which patients with higher disease activity were contacted more frequently. Eighty-six percent of patients in the pre-intervention group (n = 7) compared with 100% of patients in the post-intervention group (n = 10) had high to moderate disease activity at baseline. Within a 6-month follow-up period in both groups, the percentage of high to moderate disease activity patients decreased by 30% in the post-intervention group and remained the same in the pre-intervention group. These results support the positive impact increased specialty pharmacy services may have on clinical outcomes; therefore, the continued expansion of these services should be considered.Keywords
This publication has 7 references indexed in Scilit:
- 2021 American College of Rheumatology Guideline for the Treatment of Rheumatoid ArthritisArthritis Care & Research, 2021
- Rheumatoid ArthritisMedical Clinics of North America, 2021
- Coupled Effect of Electronic Medical Record Modifications and Lean Six Sigma Methodology on Rheumatoid Arthritis Disease Activity Measurement and Treat‐to‐Target OutcomesACR Open Rheumatology, 2021
- Outcomes and Quality of Care in Rheumatoid Arthritis With or Without Video Telemedicine Follow‐Up VisitsArthritis Care & Research, 2020
- Technology-enabled specialty pharmacy utilization of the routine assessment of patient index data 3 (RAPID3) to monitor and enhance outcomes of rheumatoid arthritis (RA) patients – a retrospective reviewJournal of Drug Assessment, 2018
- Rheumatoid Arthritis: Common Questions About Diagnosis and Management2018
- RAPID3, an Index to Assess and Monitor Patients with Rheumatoid Arthritis, Without Formal Joint Counts: Similar Results to DAS28 and CDAI in Clinical Trials and Clinical CareRheumatic Disease Clinics of North America, 2009